Answers are grounded in this paper and cite their sources.
Gemcitabine-docetaxel yielded superior progression-free and overall survival to gemcitabine alone, but with increased toxicity. Adaptive randomization is an effective method to reduce the number of patients receiving inferior therapy.
No takes yet. Share an insight, caveat, or question.
Maki et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: